Upwards arrow: Go back to top

Join us on LinkedIn for the latest news.

We use cookies to improve the user experience.
You can read more about our Cookie Policy here.
Accept

Monday, February 24, 2025

Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia